FI
NANS
In
INFECTION
RESULTS
The first quarter
· Net sales for the quarter increased 23% to 22 997 (18 708) sek · Adjusted for divested operations, the increase was 43%· EBITDA (operating income before depreciation and amortization) improved to 429 (-4 555) thousand· Earnings after tax -1 003 (-7 801) thousand· Earnings per share -0,10 (-0,75) $
IMPORTANT EVENTS
Arcoma North America Inc are sold for 8 500 thousand,Arcoma North America Inc, is sold, which provides the company with 8 500 thousand. The company makes a capital gain of eur 1 193 thousand.
Arcoma signs agreement with Canon Europe
As a part of the bet in Sweden signs a Arcoma agreement with Canon Europe. The agreement provides Arcoma entitled to under their own brand names to sell the complete x-ray unit which are integrated with Canon’s imaging systems
Arcoma signs memorandum of understanding with the Solutions For Tomorrow
Arcoma signs memorandum of understanding with the Solutions For Tomorrow concerning cooperation on the Swedish market.
AFTER THE PERIOD
Arcoma is making its first direct deal in Sweden
The company makes its first direct deal in Sweden. The deal with the S:t Göran’s Hospital is host to over 3 MILLION.
The board takes a decision on the two targeted new share issues totaling SEK 10 m. The proposed new chairman of the board Lars Kvarnhem invest 5.0 MILLION in the company, conditional upon that the annual general meeting gives consent on may 18.
The board of directors takes decision on new share issues of SEK 10.0 million, of which half of the issue is to of the nominating committee, proposed new chairman of the board of the company
The success of the iranian market continues
In may, received word on 8 systems. The order is worth MSEK 2.3.
CEO COMMENT
2017 began, with significantly better order intake and sales than what we saw in the beginning of 2016. Thanks to a lower cost structure, and slightly better margins than in the previous year, resulted in the more than 4 MILLION in increased sales of almost 5 MILLION improved operating results. It is pleasing to note that we can now look back on three consecutive quarters of positive EBITDA.
About half of the sales in the quarter were to OEM customers. We still see that the proportion of OEM sales will decrease over time, but we will continue to see large variations between the quarters.
It was a big milestone for Arcoma when we are at the end of the first quarter, won our first direktorder on the Swedish market. Precisionsystemet to S:t Görans Hospital in Stockholm was delivered already, within three weeks, and installed during the påskveckorna to be able to put into use at the beginning of may. The order is worth approximately SEK 3 million in the second quarter. After a successful installation and introduction of the S:t Görans we now look forward with confidence to the future procurements in Sweden. We are now building on our sverigeorganisation to be able to meet a greater installation and servicebas in our home market.
In the beginning of the year, we sold our u.s. subsidiary and the bordsförsäljning, as was done by the company. The deal, earning $ 8.5 MILLION and provided a capital gain of just over 1 MILLION.
We have in recent months upgraded our Intuition-series with a new product, Arcoma Intuition, where we like our flagship Arcoma Precision offers a complete x-ray unit including the picture software and digital detectors. Arcoma-series gives us the opportunity to sell the system without being dependent on a detektorleverantör when the systems are suitable for a number of detektormärken. The first systems were delivered and installed during the first quarter and is now in operation in England and Russia.
The success of the iranian market continues and we have recently received yet an order for eight systems from our distributor in Iran. The order is worth approximately SEK 2.3 million and will be delivered during the summer.
In march was held the annual fair, the ECR (European Congress of Radiology) in Vienna, Europe’s largest trade fair in the field of radiology, with more than 25 000 visitors. We were there and showed our autopositionerande Precisionsystem and the new features available in the system, which was well received by our visitors from all over the world.
We continue our investment in Asia and I just got back from a sales meeting in Hong Kong, where we gathered the majority of our distributors and several customers from the region for presentations of our new and more established products. The meeting with our actors in Asia gave me a strong belief in our continued success in the market.
Mikael Högberg
CEO, Arcoma AB (publ)
For further information, please contact:
Mikael Högberg, PRESIDENT & ceo Telephone: 0470-70 69 85, E-mail mikael.hogberg@arcoma.se
For more information about the company visit www.arcoma.se
This information is such information as the Arcoma AB is obliged to publish under the EU marknadsmissbruksförordning (MAR). The information was submitted, by the above contact person in the government, for publication on 18 may 2017 there is a 14:00
Arcoma AB Interim report In 2017-Q1
